Page last updated: 2024-11-10

21-deacetyldeflazacort

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

21-deacetyldeflazacort: RN given refers to (11beta,16beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3081431
MeSH IDM0139416

Synonyms (30)

Synonym
21-deacetyldeflazacort
l 6485
t1lwn33j2p ,
21-desacetyldeflazacort
5'betah-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 11beta,21-dihydroxy-2'-methyl-
21-desdfz
(11beta,16beta)-11,21-dihydroxy-2'-methyl-5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione
l-6485
deflazacort metabolite ii
einecs 303-069-8
13649-57-5
5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 11,21-dihydroxy-2'-methyl-, (11beta,16beta)-
deacetyldeflazacort
11beta,21-dihydroxy-2'-methyl-16alpha-5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione
unii-t1lwn33j2p
21-desacetyl deflazacort
J-006853
(11.beta.,16.beta.)-11,21-dihydroxy-2'-methyl-5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione
5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 11,21-dihydroxy-2'-methyl-, (11.beta.,16.beta.)-
5'.beta.h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 11.beta.,21-dihydroxy-2'-methyl-
(1s,2s,4r,8s,9s,11s,12s,13r)-11-hydroxy-8-(2-hydroxyacetyl)-6,9,13-trimethyl-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-16-one
5'h-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 11,21-dihydroxy-2'-methyl-, (11beta,16beta)-
(11beta,16beta)-11,21-dihydroxy-2'-methyl-5'h-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione
deflazacort related compound c
(6ar,6bs,7s,8as,8bs,11ar,12as,12bs)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10-trimethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4h-naphtho[2',1':4,5]indeno[1,2-d]oxazol-4-one
PD044132
CS-0018062
HY-100085
DTXSID201043063
AKOS040749909

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The aim of this study is to evaluate the pharmacokinetic properties of 21-OH DFZ in healthy Chinese volunteers after a single and multiple oral administration of DFZ tablets under fed condition."( [Pharmacokinetics of deflazacort tablets in healthy Chinese volunteers].
Ding, L; Ding, W; Li, WB; Lin, HD; Pan, H, 2014
)
0.4
" The method was successfully applied to a preclinical pharmacokinetic (PK) study of the six GCs on female nude mice after a single oral dose of 1 mg/kg."( Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice.
Guo, Y; Hao, C; Kong, D; Li, J; Tian, X; Xue, J; Yao, Q; Zhou, T, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
"Deflazacort (DFZ, a prodrug) is well absorbed and rapidly metabolized into the active metabolite 21-hydroxydeflazacort (21-OH DFZ) after oral administration."( [Pharmacokinetics of deflazacort tablets in healthy Chinese volunteers].
Ding, L; Ding, W; Li, WB; Lin, HD; Pan, H, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's2 (25.00)18.2507
2000's1 (12.50)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]